Lupin Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company delivered a robust performance, reporting a total annual consolidated revenue of ₹279,580.3 million and a net profit after tax of ₹53,554.7 million for the year. Following these strong results, the Board of Directors has recommended a final dividend of ₹18 per equity share, representing a 900% payout.
Annual Financial Highlights
For the financial year ended March 31, 2026, Lupin Limited demonstrated significant growth. The company achieved a consolidated revenue from operations of ₹279,580.3 million, up from ₹227,079.0 million in the previous fiscal year. Consolidated profit after tax also saw a substantial increase, reaching ₹53,554.7 million compared to ₹33,062.6 million in FY 2025. This performance reflects strong operational momentum across the company’s global portfolio.
Dividend Announcement
In recognition of the company’s solid financial standing, the Board of Directors has recommended a dividend of ₹18 per equity share on a face value of ₹2, marking a 900% dividend payout. This recommendation remains subject to approval by shareholders during the company’s upcoming Annual General Meeting (AGM). Once approved, the payout is expected to be distributed within 30 days.
Segment Performance
Lupin’s Pharmaceuticals business continues to be the primary revenue driver, contributing ₹278,123.6 million to the annual consolidated revenue. The segment reported a total profit before tax of ₹70,502.7 million for the year. While the Others segment saw a loss of ₹1,777.2 million, the overall consolidated performance underscores the resilience and scale of the company’s core pharmaceutical operations.
Strategic Developments
The company continues to expand its footprint through strategic acquisitions and settlements. Notably, the company finalized the acquisition of VISUfarma B.V. on April 1, 2026, for a total consideration of ₹20,902.7 million. Furthermore, the company successfully reached a settlement regarding the Mirabegron ER Tablets dispute, with a total payment of USD 90.0 million, aimed at resolving ongoing litigation and providing operational clarity moving forward.
Source: BSE
